The difference between other small biotechs and BOT is BOT have a team with commercial experience releasing over 25 products and grown some into billion dollar companies that have eventually been taken over. SB is BOT's first commercial product and transitions it from a pure R&D company with no income into a money making machine. The management team hand picked SB and they know they got a bargain, cost over $160m to develop and pass through the clinical process. Looking forward to the journey ahead.
Post-FDA decision price sweep, page-43
-
- There are more pages in this discussion • 82 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
38.0¢ |
Change
0.025(7.04%) |
Mkt cap ! $687.8M | |||
| Open | High | Low | Value | Volume |
| 36.5¢ | 38.0¢ | 36.0¢ | $3.158M | 8.589M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 141840 | 37.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 38.0¢ | 135173 | 2 |
View Market Depth
| Last trade - 16.10pm 24/07/2024 (20 minute delay) ? |
| BOT (ASX) Chart |